

# ezderm<sup>®</sup>

MVP Overview & 2026 Quality Measure Review



## **Mips Value Pathway (MVP) vs. Traditional MIPS**

### What to Know at the Start of the Year

- **Measure Selection.** CMS *pre-selects* which measures are eligible under that speciality MVP instead of letting you pick from the whole MIPS inventory.
- **You do not need to decide your reporting path in January.** MVPs are optional, and many practices choose later in the year.
- **The same clinical documentation supports both paths.** Quality data, Improvement Activities, and Promoting Interoperability workflows apply to MVP and Traditional MIPS.
- **Early-year focus should be on consistent data capture, not scoring optimization.** Turning off measures too early is the biggest risk.
- **Mid-year is the right time to evaluate performance and choose a path.** Data collected early preserves flexibility and avoids penalties.



## **MVP vs. Traditional MIPS**

### **Same Reporting Requirements, Fewer Measures in MVP**

Traditional Mips: Report on 6 measures

MVP: Report on 4 measures

(1 outcome or high-priority measure required)

20 Eligible Instances Needed

75% Reporting Rate

(data submission for  $\geq 75\%$  of eligible patients)



## Ezderm Quality Measures that Support 2026 MVP Pathway



### Dermatology Care MVP 2026 Measures

Measure 47: Advance Care Plan

Measure 176: Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy

**NEW** Measure 226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Measure 410: Psoriasis: Clinical Response to Systemic Medications

Measure 485: Psoriasis – Improvement in Patient-Reported Itch Severity

Measure 486: Dermatitis – Improvement in Patient-Reported Itch Severity

**NEW** Measure 509: Melanoma: Tracking and Evaluation of Recurrence

**Additional Note:** MVP 2026 supports 15 total Quality measures; this shows Ezderm-supported measures.



Ezderm supports the following **13 Quality measures** for 2026:

- [Measure 47](#): Advance Care Plan (High Priority)
- [Measure 410](#): Psoriasis - Clinical Response to Oral Systemic or Biologic Medications (Outcome measure)
- [Measure 374](#): Closing the referral Loop: Receipt of Specialist Report (High Priority)
- [Measure 130](#): Documentation of Current Medications in the Medical Record (High Priority)
- [Measure 176](#): Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy
- [Measure 485](#): Psoriasis – Improvement in Patient-Reported Itch Severity (High Priority)
- [Measure 486](#): Dermatitis – Improvement in Patient-Reported Itch Severity (High Priority)
- [Measure 317](#): Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented.
- [Measure 355](#): Unplanned Reoperation within the 30-Day Postoperative Period (High Priority & Outcome)
- [Measure 357](#): Surgical Site Infection (SSI) (High Priority & Outcome)
- [Measure 358](#): Patient-Centered Surgical Risk Assessment and Communication (High Priority)
- [Measure 226](#): Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- [Measure 509](#): Melanoma: Tracking and Evaluation of Recurrence (High Priority)

➖ CMS *removed* measure 487 in the 2026 reporting year



# Promoting Interoperability

Practice exclusion available for practices under 15 providers.

Please reach out to [customersuccess@Ezderm.com](mailto:customersuccess@Ezderm.com) if you want to learn more about PI.

The screenshot shows a web application window with a title bar containing three colored circles (red, yellow, green). The window has a header bar with a back arrow, the text "EZDERM Doctor, MD", the title "Promoting Interoperability", and a plus sign. Below the header is a list of five report entries, each with a title, last modified date, provider(s), and a right-pointing chevron.

EZDERM Doctor, MD		Promoting Interoperability	+
Promoting Interoperability Report For: Oct 1, 2024 - Dec 31, 2024	Last Modified on Dec 9, 2024	Provider(s): EZDERM Doctor, MD	>
Promoting Interoperability Report For: Jul 1, 2024 - Dec 31, 2024	Last Modified on Oct 23, 2024	Provider(s): EZDERM Doctor, MD	>
Promoting Interoperability Report For: Jul 1, 2024 - Dec 31, 2024	Last Modified on Oct 23, 2024	Provider(s): EZDERM Doctor, MD	>
Promoting Interoperability Report For: Oct 1, 2023 - Dec 31, 2023	Last Modified on Oct 23, 2024	Provider(s): EZDERM Doctor, MD	>
Promoting Interoperability Report For: Oct 1, 2021 - Dec 31, 2021	Last Modified on Feb 13, 2023	Provider(s): EZDERM Doctor, MD	>




## **How to Pull Quality Report In Ezderm**



## Interactive Quality Report

Now found under each Admin  
& Provider EHR Login. This  
allows Admins to help monitor  
progress throughout the year.







EZDERM Doctor, MD, PHD		Quality Reports		
31, 2025	>	Generate Report	Refresh	Delete
Report For: Jan 1, 2024 - Dec 31, 2024				
Last Modified on Jan 24, 2024				
Provider: EZDERM Doctor, MD, PHD				
Report For: Jan 1, 2022 - Dec 31, 2022				
Last Modified on Jan 30, 2023				
Provider: EZDERM Doctor, MD, PHD				

Don't forget to refresh report to see updates!

Swipe left to  
Refresh the Report



### Performance Rate =

All visits that met the criteria /  
(patients that have completed visits -  
patients that were excluded)

**Goal = 100%**

**Note:** 2nd year we are seeing  
INVERSE Performance Rates for  
select measures

### Reporting Rate =

(MET + NOT MET + Exclusions) /  
visits that passed the Denominator

**Goal = Greater than 75%**

Cancel		Report For: Jan 1, 2025 - Dec 31, 2025	Personal Note Done
47 - Advance Care Plan			i
Performance Met		1	
Denominator		1	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		100.00 %	
Reporting Rate		100.00 %	
Eligible Patients		>	
130 - Documentation of Current Medications in the Medical Record			i
Performance Met		0	
Denominator		2	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		0.00 %	
Reporting Rate		0.00 %	
Eligible Patient Visits		>	
176 - Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy			i
Performance Met		0	
Denominator		0	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		0.00 %	



Cancel		Report For: Jan 1, 2025 - Dec 31, 2025	Personal Note Done
47 - Advance Care Plan			i
Performance Met		1	
Denominator		1	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		100.00 %	
Reporting Rate		100.00 %	
Eligible Patients		>	
130 - Documentation of Current Medications in the Medical Record			i
Performance Met		0	
Denominator		2	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		0.00 %	
Reporting Rate		0.00 %	
Eligible Patient Visits		>	
176 - Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy			i
Performance Met		0	
Denominator		0	
Performance Not Met		0	
Performance Exclusion		0	
Performance Rate		0.00 %	

## Quality Report

Tap “Eligible Patients”  
to review patient  
responses contributing  
to the score and any  
Incomplete measures

**Additional Note:** Measure 226 and 509  
(new in 2026) are **not yet available in  
the report**, but will be coming soon.



Eligible Patients For 317

Patient Category:

All Met Not Met Excluded Denominator Incomplete

Matthew Danto  
Date Of Service: Jan 9, 2025  
Medical Record Number: MADA0001  
Date Of Birth: Jan 29, 1987

Micheal Andres  
Date Of Service: Jan 16, 2025  
Medical Record Number: MIAN0000  
Date Of Birth: Mar 11, 1980  
Insurance Companies: Commercial Insurance - Auth and Referral Required

Olivia Cassar  
Date Of Service: Jan 20, 2025  
Medical Record Number: OLCA0001  
Date Of Birth: Jan 1, 1990

Test Adriana  
Date Of Service: Jan 2, 2025  
Medical Record Number: TEAD0001  
Date Of Birth: Jan 1, 1980  
Insurance Companies: Empire BCBS New York

Test Lynn  
Date Of Service: Jan 3, 2025  
Medical Record Number: LYGO0001  
Date Of Birth: May 6, 1990  
Insurance Companies: Blue Cross Blue Shield of Illinois - BCBS, Aetna

Wanda James  
Date Of Service: Jan 13, 2025  
Medical Record Number: WAJA0000  
Date Of Birth: Mar 15, 1990  
Insurance Companies: Blue Cross Blue Shield of Illinois - BCBS, Blue Shield - Florida

## Incomplete Patients

Under eligible patients, review Incomplete visits if reporting rate is low

Click into each Incomplete patient to answer the MACRA question for the corresponding Encounter



After clicking the “M” from the Progress Note, answer the question to complete the measure

Met

Excluded

Not Met

130 - Documentation of Current Medications in the Medical Record

SELECT ONE:

- ☒ G8427: Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications
- ☐ G8430: Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an urgent or emergent medical situation)
- ☐ G8428: Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given

TIP: NOTE: The MIPS eligible clinician must document in the medical record they obtained, updated, or reviewed a medication list on the date of the encounter. MIPS professional or MIPS eligible clinicians submitting this measure may document medication information received from the patient, authorized representative(s), caregiver(s) or other available healthcare resources.

This list must include ALL known prescriptions, over-the-counter (OTC) products, herbals, vitamins, minerals, dietary (nutritional) supplements, cannabis/cannabidiol products AND must contain the medications' name, dosage, frequency and route of administration.

By submitting the action described in this measure, the provider attests to having documented a list of current medications utilizing all immediate resources available at the time of the encounter. G8427 should be submitted if the MIPS eligible clinician documented that the patient is not currently taking any medications.

Definitions:

Current Medications - Medications the patient is presently taking including all prescriptions, over-the-counters, herbals, vitamins, minerals, dietary (nutritional) supplements, and cannabis/cannabidiol products with each medication's name, dosage, frequency and administered route

Route - Documentation of the way the medication enters the body (some examples include but are not limited to: oral, sublingual, subcutaneous injections, and/or topical).

Not Eligible (Denominator Exception) - patient is not eligible if there is documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an urgent or emergent medical situation where time is of the essence and to delay treatment would jeopardize the patient's health status).

< Previous Question



## **Tip: Schedule a Monthly Quality Report Review**

**Incorporate into your end-of-month routine**



### **Avoid Year-End Surprises**

Don't wait until Q4 to discover low performance, and track and improve throughout the year.



### **Support Your Team Proactively**

Provide timely retraining for users who consistently miss MIPS measures.



### **Protect Incentives and Avoid Penalties**

Consistent tracking helps ensure you meet thresholds to secure bonuses and avoid CMS penalties



## **Quality Measure Descriptions & Tips**



## MIPS Measure #226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

### **Description:**

Percentage of patients aged 12 years and older who were screened for tobacco use one or more times within the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.

### **Tips**

- Watch workflow video: [#226](#)
- If the measure is not triggering, please confirm that an E&M code is present, as the measure is triggered by an E&M.

### **To trigger this measure within Ezderm**

- When an eligible patient encounter with a qualifying E&M or CPT code is recorded, measure #226 will appear in the Available Measures list.
- Select the appropriate screening outcome and indicate whether a tobacco cessation intervention was provided.
- Tap Done to save and complete the measure.





## MIPS Measure #509: Melanoma: Tracking and Evaluation of Recurrence

### **Description:**

Percentage of patients who had an excisional surgery for melanoma or melanoma in situ with initial American Joint Committee on Cancer (AJCC) staging of 0, I, or II, in the past 5 years in which **the operating clinician examines and/or diagnoses the patient for recurrence of melanoma.**

### **Tips**

- **Denominator Is Limited to the Clinician who performed the excision**
- **2 Submission Criteria for the Numerator:** Documentation by the clinician who performed the surgery that an exam for recurrence of melanoma was performed on the patient within the performance period **AND** All patients that were diagnosed with a recurrent melanoma in the current performance period



### **To trigger this measure within Ezderm**

- When an eligible patient with a previously documented melanoma (see diagnoses below) and a qualifying E&M encounter is recorded, the #509 measure will appear
- Select the appropriate option for both numerator questions (note this is an **Inverse Measure**)

**Diagnosis for Melanoma or Melanoma in situ (ICD-10-CM):** C43.0, C43.10, C43.111, C43.112, C43.121, C43.122, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9, D03.0, D03.10, D03.111, D03.112, D03.20, D03.121, D03.122, D03.30, D03.39, D03.4, D03.51, D03.52, D03.59, D03.60, D03.61, D03.62, D03.70, D03.71, D03.72, D03.8, D03.9



## MIPS Measure #47: Advance Care Plan (Living Will)

**Description:** Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan.

### Tips

- The Advance Directive question can be enabled in your EZ Check-In settings, so patients are asked this question during their check-in process.
- Add a note under **History > Advance Healthcare Directive > Active Living Will**, click on black text > **Note** to indicate whom is the surrogate decision maker, relationship, and optional phone number.
- **The name of the surrogate is NOT required**; just that one has been identified. By answering YES or NO you will receive credit, but if NO you must document that the patient did not want to name a surrogate or discuss a care plan.

The image shows a screenshot of the EZ Check-In form with a blue arrow pointing to the 'Advance Healthcare Directive' section. The form includes sections for 'Sexual Orientation' (Bisexual, Homosexual, Heterosexual, Not sexually active) and 'Advance Healthcare Directive' (Active living will, No advance directive). The 'Active living will' option is selected. A pop-up window titled 'Advance Healthcare Directive' is shown, displaying 'Finding: Active living will' and 'Presence: Yes'. The 'Note' field contains the text 'Cousin Samantha is healthcare surrogate'.




## MIPS Measure #130: Documentation of Current Medications in the Medical Record

**Description:** Percentage of visits for patients over the age of 18 for which the eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This not only applies for prescriptions but for all medications, included vitamins, minerals, supplements and OTC products.

### Tips

- “Merit- based Incentive Payment System (MIPS) eligible clinicians meet the intent of this measure by **making their best effort** to document a current, complete and accurate medication list during each encounter. ”
- Use Dispensed **Medication and/or Medications** you can document dosage/route/frequency in the Note section (click on name of Rx > Note)
- Optional: Add **Medication Reconciliation Treatment Plan** (found in public database)







## **MIPS Measure #130: Documentation of Current Medications in the Medical Record**

**Description:** Percentage of visits for patients over the age of 18 for which the eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This not only applies for prescriptions but for all medications, included vitamins, minerals and supplements

### **Tips Continued...**

- Under **History > Dispensed Medication**, click on the  to document the patient's current medications from the pharmacy if a Medication Consent was signed.
- Activate **EZLINK Check In via SMS** and patients can select past medications from SureScripts Dispensed medications list (email [customersuccess@Ezderm.com](mailto:customersuccess@Ezderm.com) to learn more!)



**Dispensed Medications** ⓘ

Our records show the medications listed below have been dispensed to you. Please check all that you are currently taking. ⓘ

- ☐ 12 HR cetirizine HCl 5 MG / Pseudoephedrine HCl 120 MG ER Oral Tablet  
Dispensed on September 13, 2023
- ☐ Suboxone 8 mg-2 mg sublingual film  
Dispensed on September 13, 2023
- ☐ Daklinza 60 mg tablet  
Dispensed on August 09, 2023
- ☐ Buprenorphine 2 MG / Naloxone 0.5 MG Sublingual Tablet  
Dispensed on June 20, 2023

**Next**

**LA**  
100 Main Street, Los Angeles, CA 90017  
(333) 333-3333 • [www.laladerm.com](http://www.laladerm.com)




## MIPS Measure #176: Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy

**Description:** If a patient aged 18 years and older has been newly prescribed a biologic/immune response modifier that includes a warning for potential reactivation of a latent infection, then medical record should indicate TB testing in the preceding 12-month period

### Tips

- To be eligible, the patient must not have been prescribed any biologic or immune response therapy in the **15 months preceding the encounter** at which the biologic and/or immune response modifier was newly started.
- Treatment Plan available in the public database titled **TB Screening (MACRA Measure 176)** to document TB test done within the last 12 months



**Assessment and Plan** ●●●○

1. Psoriasis

- Problem: Chronic - Stable
- Body Surface Area (BSA): 7.0 %
- Locations: Chest, Anterior Left Upper Arm - Proximal
- Plan:
  - Patient is being prescribed a biologic and/or immune response modifier that includes a risk of potential reactivation of latent infection. Due to this it has been confirmed that the patient has received TB testing within the last 12 months, and prior to this medication being prescribed.
  - Medications: brodalumab 210 mg Syringe subcutaneous, 1.0 Application, QD, 30 Days, 1.5 Milliliters. 1(one) application(s) subcutaneous every day


**Counseling**

## MIPS Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

**Description:** Percentage of patient visits for patients aged 18 years and older seen during the performance period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive

### Tips

- Document BP within the Progress Note by going to **Vital Signs > Systolic/Diastolic**
  - **Automation:** If Normal BP, follow up plan not required and question automatically answered
- To be submitted at each visit during the reporting period
- If **BP is elevated or hypertensive**, recommend and document follow up, such as referring to PCP
  - The documented follow-up plan must be related to the current BP reading as indicated, example: "Patient referred to primary care provider for BP management"
- **Denominator Exception:** Patients with an active diagnosis of hypertension in the last 12 months are not eligible. Must be a new occurrence of hypertension and cannot be currently treated by another provider.



The screenshot shows a medical chart interface for a patient named Wendy Willow (♀ 34 | 04/21/1990). The date is Wednesday, January 29, 2025. The interface includes a top navigation bar with icons for Alerts (4), Notes (3), Consents (1), With Provider (WR), MACRA, 99214, Forms, and Rx Order. The main content area is divided into sections: Review of Systems, Vital Signs, and Physical Exam. The Vital Signs section shows a blood pressure reading of 110/70 mmHg. The Physical Exam section describes salmon pink erythematous plaques with fine white scale on the back, right anterior forearm, and proximal, anterior left upper arm.



## **MIPS Measure #355: Unplanned Reoperation within the 30-Day Postoperative Period**

**Description:** Percentage of patients aged 18 years and older who had any unplanned reoperation within the 30-day postoperative period.

### **Tips**

- **INVERSE MEASURE** – The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control.
- Measure only applies to patients who undergo procedures by November 30th of the performance period to allow for the 30 days postoperative period
- We recommend either of these methods to manage this measure:
  - Answering this question as “NO” but if the patient returns with an Unplanned Reoperation within 30 days you can go back into the Encounter and mark the measure as YES
  - OR -
  - Waiting until 31+ days after the surgery to answer question. By choosing this option the system will capture these patients within the Incomplete section of your Quality Report

**GOAL=**  
**0%**  
**Performance**

### **To trigger this measure within Ezderm**

- The encounter must include a specific surgical CPT code. A full list of applicable codes can be found [here](#)



### **MIPS Measure #357: Surgical Site Infection (SSI)**

**Description:** Percentage of patients aged 18 years and older who had a surgical site infection (SSI) that occurs within 30 days after the operation

#### **Tips**

- **INVERSE MEASURE** – The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control.
- Measure only applies to patients who undergo procedures by November 30th of the performance period to allow for the 30 days postoperative period
- We recommend either of these methods to manage this measure:
  - Answering this question as “NO” but if the patient returns with a SSI within 30 days you can go back into Encounter and mark the measure as YES
  - OR -
  - Waiting until 31+ days after the surgery to answer question. By choosing this option the system will capture these patients within the Incomplete section of your Quality Report

**GOAL=**  
**0%**  
**Performance**

#### **To trigger this measure within Ezderm**

- The encounter must include a specific surgical CPT code. A full list of applicable codes can be found [here](#)





### MIPS Measure #358: Patient-Centered Surgical Risk Assessment and Communication

**Description:** Percentage of patients age 18 and over who underwent a non-emergency surgery who had their personalized risks of postoperative complications assessed by their surgical team prior to surgery using a clinical data-based, patient-specific risk calculator and who received personal discussion of those risks with the surgeon

#### Tips

- Must document the surgical risk by using a **risk calculator**:
  - *“Risk calculators based on multi-institutional, validated clinical data are acceptable for this measure. ACS NSQIP offers a risk calculator, which can be used for operations in many surgical subspecialties ”*
- CMS is flexible on allowing providers to use the tools they believe is best for their patient population as long as they are **validated tools**.

#### To trigger this measure within Ezderm

- The encounter must include a specific surgical CPT code. A full list of applicable codes can be found [here](#)



## **MIPS Measure #374: Closing the Referral Loop: Receipt of Specialist Report**


**Description:** Percentage of patients regardless of age with referrals for which the referring clinician receives a report from the clinician to whom the patient was referred

### Tips

- **Automation** of this measure available by sending via Referrals Icon > creates order in Inbox to track > Upload results from PM > Export/Import Results > create order in Pending Review for the Provider
- You are **not required to send a referral out through Ezderm**, but you will need to upload the report to the chart from the provider to whom the patient was referred if not following above steps
- Only first referrals made between January 1 – October 31 (the measurement period) will count towards the denominator to allow adequate time for the referring clinician to collect the consult report by the end of the performance period
- Referral can be made between providers from the same practice

### To trigger this measure within Ezderm

- E&M Code Present (Apply Treatment Plan(s))






## MIPS Measure #410: Psoriasis: Clinical Response to Systemic Medications

**Description:** Percentage of all psoriasis vulgaris patients regardless of age receiving systemic medication who meet minimal physician-or patient- reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.

### Tips

- Diagnosis in treatment plan or impression field must be **Psoriasis Vulgaris** (not just Psoriasis)
- **BSA** (which calculates automatically based on locations selected), **PASI** or **PGA** scores can be viewed from the body map. Click on BSA to click through to PASI & PGA, long hold on each to indicate the severity. Or access PASI from wheel icon.






## MIPS Measure #485: Psoriasis Improvement in Patient-Reported Itch Severity

**Description:** The percentage of patients aged 8 years and older, with a diagnosis of psoriasis where at an initial visit have a patient-reported itch severity assessment performed, score greater than or equal to 4, and who achieve a score reduction of 3 or more points at a follow-up visit.

### Tips

- In the first encounter the measure will not automatically trigger, you need to add a **Pruritus Itch Score** from the 😊 icon at the bottom of the Physical Exam screen.
- For the subsequent appointments, the system will automatically answer the measure if you document the itch severity changes.
- These measures now apply to all follow-up encounters containing any diagnosis from their CMS diagnosis groups, rather than only the initial visit. Each measure is tied to the visit.
- A 3+ point reduction can occur over multiple visits.



If the icon isn't in your top row, long-press on the icon and drag it up for quicker access.




## **MIPS Measure #486: Dermatitis - Improvement in Patient-Reported Itch Severity**

**Description:** The percentage of patients aged 8 years and older, with a diagnosis of dermatitis where at an initial (index) visit have a patient-reported itch severity assessment performed, score greater than or equal to 4, and who achieve a score reduction of 3 or more points at a follow-up visit.

### **Tips**

- In the first encounter the measure will not automatically trigger, you need to add a Pruritus Itch Score from the 😊 icon at the bottom of the Physical Exam screen.
- For the subsequent appointments, the system will automatically answer the measure if you document the itch severity changes.
- These measures now apply to all follow-up encounters containing any diagnosis from their CMS diagnosis groups, rather than only the initial visit. Each measure is tied to the visit.
- A 3+ point reduction can occur over multiple visits.



**If the icon isn't in your top row,  
long-press on the icon and drag it up for  
quicker access.**



## NEW 2026 Measures

**GOAL=**  
**0%**  
**Performance**

### **#509: Melanoma: Tracking and Evaluation of Recurrence (*Inverse Performance Measure*)**

*Percentage of patients who had an excisional surgery for melanoma or melanoma in situ with initial American Joint Committee on Cancer (AJCC) staging of 0, I, or II, in the past 5 years in which the operating clinician examines and/or diagnoses the patient for recurrence of melanoma.*

**Support Portal Link To Quality Measure Videos: [#226](#) and [#509](#) or [all](#)**

**Diagnosis for Melanoma or Melanoma in situ (ICD-10-CM):** C43.0, C43.10, C43.111, C43.112, C43.121, C43.122, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9, D03.0, D03.10, D03.111, D03.112, D03.20, D03.121, D03.122, D03.30, D03.39, D03.4, D03.51, D03.52, D03.59, D03.60, D03.61, D03.62, D03.70, D03.71, D03.72, D03.8, D03.9



## Additional Resources

- Find detailed videos on all measures on our support portal [here](#)
- For more information on bridging with Healthmonix, a CMS-certified data registry, see [this](#) article.
- For steps on how to pull a Quality report through Ezderm, see [here](#)
- CMS Quality Requirements [here](#)
- Check QPP Participation Requirements per provider: [here](#)

## Final Takeaways & Action Items



### Self Check:



**Is my staff answering all MACRA measures that are triggered?**

Ensure everyone understands the importance of documentation



**Have I selected the 6 Quality Measures I plan to report for MIPS?**

Pick measures where you can perform consistently well



**When was the last time I ran a Quality Report in Ezderm?**

Monthly review helps avoid end-of-year surprises



### Prepare for September: Reporting Integration Request

- Mark your calendar to request **MIPS reporting integration** in September
- When ready, email: [techsupport@Ezderm.com](mailto:techsupport@Ezderm.com) include the following information:
  - Will you be reporting as a **Group or Individual?**
  - Provide **NPI numbers** for all reporting providers



ez

**THANK YOU!**